Insurance officials cite large ACA rate filings and prior‑authorization volumes; Novo Nordisk presents semaglutide data as lawmakers probe coverage and cost

Insurance Commissioner Mike Cheney and Department of Insurance staff told the legislature’s study committee that recent filings and regulatory work on managed‑care certification and network adequacy will shape upcoming recommendations — and that the state faces high rate filings and heavy prior‑authorization workloads.

"The average increase is 40.9% for all the plans on ACA," Commissioner Mike Cheney told the committee, calling attention to recent filings the department received and to changes at the federal level that could affect prior‑authorization rules. Cheney said rough calculations indicate the state could see "about 200,000 more people" become uninsured if certain subsidies lapse, and he linked those enrollment pressures to potential strain on hospital finances in parts of the state.

Cheney described regulatory steps the Mississippi Department of Insurance (MID) has adopted, including managed‑care network adequacy and plan certification standards. He said MID requires each managed‑care entity to file an electronic provider roster by Jan. 1 of the calendar year and to submit annual prior‑authorization and utilization summaries by June 1.

The commissioner and staff walked the committee through department data showing very large prior‑authorization volumes for some plans (one company was cited as having about 400,000 prior‑authorization requests with an insured base of roughly 40,000) and an appeals reversal rate approaching 40%. Bob Williams, the department’s director of life, health and actuarial matters, and David Browning, deputy commissioner, were present to explain reporting mechanics and public access through MID’s CERB filing system.

Meanwhile, Paula Watley, a regional account manager for Novo Nordisk, introduced Dr. Courtney Walker, the company’s medical account director for managed markets, who presented clinical trial and real‑world analyses of semaglutide, a GLP‑1 molecule. Walker summarized trial results the company highlighted to the committee — including trial and observational numbers the presenter said showed reductions in cardiovascular events and kidney outcomes and substantial average weight loss — and referenced an upcoming FDA PDUFA date for a MASH (fatty‑liver) indication.

"Semaglutide is one of the only GLP‑1s that has an indication in chronic kidney disease to lower the risk of negative outcomes," Dr. Walker said, and he noted a pending PDUFA date of Aug. 19 for the MASH indication. Walker also cited a Komodo database real‑world analysis and said mean total medical costs were $4,639 lower over a year for patients on semaglutide compared with matched controls in the study he described.

Practicing clinicians on the panel urged caution and targeting. Dr. Jennifer Bridal, a family physician, told the committee patients are eager for the drugs but that retail prices are high — she said retail cost is typically about $1,000 per month while some market offers have fallen to roughly $499 — and argued the committee should prioritize coverage for high‑risk groups, such as patients with heart disease, sleep apnea and kidney disease, where short‑term budget tradeoffs could yield downstream savings.

"We finally have something that works," Bridal said, while cautioning that broad, immediate coverage could be unaffordable for plans unless carefully targeted. Several members asked the department and presenters about comparisons to bariatric surgery, long‑term maintenance of weight loss, and potential benefits in alcohol use disorder; Dr. Walker confirmed ongoing research in those areas and offered to share trial references and slides with the committee.

Committee members also flagged rural access concerns: department staff and legislators said network adequacy and managed‑care changes could have disproportionate effects in counties without nearby hospitals or comprehensive university centers, and asked staff to consider rural penetration strategies when drafting recommendations.

The committee did not vote on coverage policy at the meeting; members directed staff to circulate the department’s slide materials and datasets, and asked the presenters to provide additional trial details to support future deliberations. The committee will continue study over upcoming meetings and is required to submit its report by Dec. 1, 2025.